Literature DB >> 16232228

Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine.

A W Zuercher1, M A Imboden, S Jampen, D Bosse, M Ulrich, H Chtioui, B H Lauterburg, A B Lang.   

Abstract

Humoral immunity in response to an octavalent O-polysaccharide-toxin A conjugate Pseudomonas aeruginosa vaccine is well studied, and a Phase III clinical study in cystic fibrosis (CF) patients is currently ongoing. In contrast, little is known about cellular immunity induced by this vaccine. Fifteen healthy volunteers were immunized on days 1 and 60. Parameters of cellular immunity were studied before vaccination on day 1, and on day 74. Analyses included flow cytometry of whole blood, and antigen-induced proliferation of and cytokine production by lymphocyte cultures. The effects of immunization on the composition of peripheral blood lymphocytes as determined by flow cytometry were minor. In contrast, after immunization a highly significant increase of proliferation in response to stimulation with detoxified toxin A was noted: the stimulation index rose from 1.4 on day 1 to 42.2 on day 74 (restimulation with 0.4 microg/ml; P = 0.003). Immunization led to significant production of interferon (IFN)-gamma and tumour necrosis factor (TNF)-alpha by antigen-stimulated lymphocytes. In contrast, no significant induction of interleukin (IL)-4 or IL-10 was observed. In conclusion, immunization of healthy volunteers led to activation of cellular immunity including strong antigen-specific proliferation and cytokine production. In CF patients priming of the cellular immune system towards a Th1-like pattern would be of potential advantage. Therefore, confirmatory analyses in immunized CF patients with and without chronic infection with P. aeruginosa are foreseen.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16232228      PMCID: PMC1809510          DOI: 10.1111/j.1365-2249.2005.02925.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  20 in total

1.  Selective bystander proliferation of memory CD4+ and CD8+ T cells upon NK T or T cell activation.

Authors:  G Eberl; P Brawand; H R MacDonald
Journal:  J Immunol       Date:  2000-10-15       Impact factor: 5.422

2.  Immunization with Haemophilus influenzae type b-CRM(197) conjugate vaccine elicits a mixed Th1 and Th2 CD(4+) T cell cytokine response that correlates with the isotype of antipolysaccharide antibody.

Authors:  K K Kamboj; C L King; N S Greenspan; H L Kirchner; J R Schreiber
Journal:  J Infect Dis       Date:  2001-08-22       Impact factor: 5.226

3.  The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 type.

Authors:  C Moser; S Kjaergaard; T Pressler; A Kharazmi; C Koch; N Høiby
Journal:  APMIS       Date:  2000-05       Impact factor: 3.205

4.  Significant variation in serotype-specific immunogenicity of the seven-valent Streptococcus pneumoniae capsular polysaccharide-CRM197 conjugate vaccine occurs despite vigorous T cell help induced by the carrier protein.

Authors:  Kulwant K Kamboj; H Lester Kirchner; Rhonda Kimmel; Neil S Greenspan; John R Schreiber
Journal:  J Infect Dis       Date:  2003-04-30       Impact factor: 5.226

5.  Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans.

Authors:  S J Cryz; E Fürer; A S Cross; A Wegmann; R Germanier; J C Sadoff
Journal:  J Clin Invest       Date:  1987-07       Impact factor: 14.808

6.  Antigen-driven expansion and contraction of CD8+-activated T cells in primary EBV infection.

Authors:  Y Hoshino; T Morishima; H Kimura; K Nishikawa; T Tsurumi; K Kuzushima
Journal:  J Immunol       Date:  1999-11-15       Impact factor: 5.422

7.  Chronic Pseudomonas aeruginosa lung infection is more severe in Th2 responding BALB/c mice compared to Th1 responding C3H/HeN mice.

Authors:  C Moser; H K Johansen; Z Song; H P Hougen; J Rygaard; N Høiby
Journal:  APMIS       Date:  1997-11       Impact factor: 3.205

8.  Activation of cell-mediated immunity following immunization with pneumococcal conjugate or polysaccharide vaccine.

Authors:  T Wuorimaa; H Käyhty; J Eskola; A Bloigu; O Leroy; H M Surcel
Journal:  Scand J Immunol       Date:  2001-04       Impact factor: 3.487

9.  Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection.

Authors:  Alois B Lang; Anna Rüdeberg; Martin H Schöni; John U Que; Emil Fürer; Urs B Schaad
Journal:  Pediatr Infect Dis J       Date:  2004-06       Impact factor: 2.129

Review 10.  Lung infections associated with cystic fibrosis.

Authors:  Jeffrey B Lyczak; Carolyn L Cannon; Gerald B Pier
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

View more
  1 in total

Review 1.  Pseudomonas aeruginosa: Recent Advances in Vaccine Development.

Authors:  Matthew Killough; Aoife Maria Rodgers; Rebecca Jo Ingram
Journal:  Vaccines (Basel)       Date:  2022-07-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.